A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.
Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new ...
Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...
Patients taking the drugs eat less and they can experience side effects such as nausea, so they should prioritize certain ...
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
7h
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Weight loss with Ozempic or Wegovy can come with nausea, but avoiding certain foods and drinks can help patients manage the ...
The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...
Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback